Search the Newsreel

Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA

This article provides a financial overview of Zevra Therapeutics, Inc. (FWB:1GDA) on the Frankfurt Stock Exchange, focusing on its price-to-earnings forward metric. It highlights that the market is currently closed with no trades. The content is sourced from FactSet and ICE Data Services.

Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics

Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, valued at $77,859, according to a recent SEC filing. The company's financials show a positive revenue trend with 53.25% growth, a high gross margin of 96.16%, but a …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (ZVRA) following a significant stock price drop. The investigation stems from the European Medicines Agency's negative opinion on Zevra's Marketing Authorization Application for arimoclomol, a drug for Niemann-Pick disease type C. Investors …

Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock

Zevra Therapeutics Director Corey Michael Watton sold 12,300 shares of the company's stock for $138,375.00, reducing his holdings by 87.23% to 1,800 shares. This transaction follows a strong quarterly earnings report where ZVRA exceeded both EPS and revenue estimates. Analysts maintain a "Moderate Buy" …

Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA

Dimensional Fund Advisors LP significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 259.2% in the first quarter, purchasing an additional 400,336 shares to bring its total holdings to 554,802 shares valued at $5.168 million. Other institutional investors also adjusted their positions in …

Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA

Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data

Zevra Therapeutics' stock (ZVRA) rose 21.6% following strong Q2 2026 sales of US$39.66 million, driven by high uptake of its Niemann-Pick disease type C therapy, MIPLYFFA. New four-year real-world data for arimoclomol (MIPLYFFA's active ingredient) could be crucial for European regulatory re-examination, potentially reshaping …

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

Zevra Therapeutics (ZVRA) has released new long-term real-world safety and effectiveness data for arimoclomol in adults with Niemann-Pick disease type C, aiming to support its equity story and regulatory efforts in Europe. This data will be crucial as the company seeks a re-examination of …

Zevra Therapeutics (ZVRA) Stock Jumps On Profitability While MIPLYFFA Concentration Lingers

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in the company's stock …

Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure

FMR LLC and Abigail P. Johnson have disclosed an 8.3% beneficial ownership stake in Zevra Therapeutics (ZVRA) through a Schedule 13G/A filing. FMR LLC has sole voting power over 4,899,562 shares and sole dispositive power over 4,915,717 shares, while Abigail P. Johnson holds sole …

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings

Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside

Zevra Therapeutics, Inc. (ZVRA) has seen its average 12-month price target increase from $24.78 to $25.11, according to estimates from nine analysts. This updated target implies a significant 138% potential upside from the August 5 closing price, with individual forecasts ranging from $20 to …

ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54

Zevra Therapeutics (NASDAQ: ZVRA) appears significantly undervalued according to GuruFocus' GF Value™, trading at $10.54, which is 54.4% below its intrinsic value estimate of $23.11. Despite strong Q2 2026 revenue growth driven by its product MIPLYFFA, the company's GF Score™ of 64/100 indicates moderate …

Zevra Therapeutics Reports Strong Q2 2026 Earnings with Growth in MIPLYFFA

Zevra Therapeutics announced robust Q2 2026 earnings, reporting $39.7 million in net revenue, a 53% year-over-year increase, largely driven by $30.2 million in U.S. sales of MIPLYFFA. The company also strengthened MIPLYFFA's intellectual property with an Orange Book listing extending to 2041. Despite strong …

Is Zevra Therapeutics Inc (ZVRA) Underperforming After Q2 2026 E

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) reported strong Q2 results, with earnings of $0.25 per share significantly beating the Zacks Consensus Estimate of $0.08, and revenues of $39.66 million surpassing estimates by 22.76%. Despite this positive performance and a 17.4% year-to-date stock increase, the company currently holds …

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary

Zevra Therapeutics, Inc. reported strong financial results for the quarter ended 2026, with revenue reaching $39.66M and diluted EPS of $0.14, primarily driven by the commercialization of MIPLYFFA. The company highlighted significant revenue growth, successful market penetration for MIPLYFFA, and ongoing progress in its …

Zevra Therapeutics, Inc. GAAP EPS of $0.14 beats by $0.03, revenue of $39.7M beats by $5.82M

* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20608774-zevra-reports-second-quarter-2026-financial-results-and-corporate-update] (ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q2 GAAP EPS of $0.14 beats by $0.03. * Revenue of $39.7M (+53.4% Y/Y) beats by $5.82M. * * Cash Position: Cash, cash equivalents and investments were $260.2 million as of June 30, 2026. Based …

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics reported strong second-quarter 2026 financial results, with $39.7 million in net revenue, a 53% increase over Q2 2025, primarily driven by MIPLYFFA sales. The company achieved a net income of $8.8 million and maintained a robust cash position of $260.2 million, which …

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will deliver the presentation, and management will also be available for one-on-one meetings with registered conference …

Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results

Q2 2026 Zevra Therapeutics Inc Earnings Call Transcript

Key Points Interested in Zevra Therapeutics, Inc.? Here are five stocks we like better. Revenue grew strongly: Zevra's Q2 2026 net revenue rose 53% year over year to $39.7 million, led by MIPLYFFA U.S. revenue of $30.2 million. Adjusted net income was $15.2 million, …

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) posts Q2 profit, repays debt

Zevra executives set to present at Boston growth conference

Zevra Therapeutics announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 11:00 a.m. ET. Management will also be available for one-on-one meetings, and a live webcast of the …

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky has initiated a securities investigation into Zevra Therapeutics (ZVRA) following a significant 24% stock drop on July 24, 2026. This decline occurred after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa. …

Zevra Therapeutics Announces Publication of 4-Year Real-World Data on MIPLYFFA in Niemann-Pick Disease Type C

Zevra Therapeutics has announced the publication of 4-year real-world data on its drug MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) in Molecular Genetics and Metabolism. The study, involving 109 participants, demonstrated long-term safety and effectiveness, showing stable disease severity over time, particularly for …

Zevra's First Published Adult Niemann-Pick Data Includes Up to 4 Years

Zevra Therapeutics announced the publication of four-year real-world data from its U.S. Early Access Program for MIPLYFFA (arimoclomol) in Niemann-Pick disease type C (NPC). The study, detailed in Molecular Genetics and Metabolism, followed 109 participants, including 53 adults, and showed that disease severity remained …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Zevra Therapeutics, Inc. (ZVRA) following a negative opinion from the European Medicines Agency regarding its drug, arimoclomol, which caused a sharp drop in Zevra's stock price. The firm is encouraging investors who purchased Zevra …

Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA)

This article provides recent news headlines related to Zevra Therapeutics, Inc. (ZVRA), including multiple investor alerts about investigations into the company. It also mentions a presentation of new data and a resubmission of a New Drug Application to the FDA. The stock's current delayed …

Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency's CHMP regarding the Marketing Authorization Application for arimoclomol, which caused a sharp drop …

Zevra Therapeutics Market Sentiment

This article provides an overview of Zevra Therapeutics (ZVRA) market sentiment, including analyst consensus, short interest, and recent insider activity. It highlights that 15 analysts have a "Buy" consensus with an average price target of $23, and mentions several recent insider acquisitions of stock …